foxo4 dri human trials results The disordered p53 transactivation domain is the target of and the senolytic compound FOXO4-DRI PDF) Senolytic Peptide FOXO4-DRI Selectively

The capsule format protects the peptide from premature degradation and allows for precise dosing without measuring or drawing doses as required with injectable formulations

Description 5-Amino-1MQ 50mg 5-Amino-1MQ (5-Amino-1-Methylquinolinium) is a synthetic small molecule classified as a methylquinolinium compound and structurally derived from research investigating nicotinamide-related cellular biochemistry

A few salient observations: note the different methods of denervation and effect size (bottom row) is the effect size indeed larger with longer follow up (among the three newer trials: greatest effect at the 6 month vs the 2 month follow up)

Its a popular choice because the muscle is substantial, and the area typically has fewer nerve endings, which can mean less discomfort during the injection

Copp, P.-Y